Dearest Entourage,

Emily’s Entourage (EE) has grown in many ways since our founding more than 13 years ago. It’s an evolution that’s taken us from plucky start-up to established leader in accelerating research and drug development for individuals in the final 10% of the cystic fibrosis (CF) community. 

Throughout the past two years, we’ve seen EE’s progress unfold in remarkable and transformative ways. For the first time, EE-funded research has advanced through the pipeline to clinical trials. Phages developed through EE support are now being used to treat people with antibiotic-resistant infections. EE’s innovative patient database and clinical trial matchmaking program are emerging as impactful tools in expediting clinical trial recruitment and, in turn, accelerating the development of lifesaving therapies. EE has received a record number of grant applications from researchers from around the globe.

Still, we have our work cut out for us. The urgent need remains for treatments for the final 10% of people with CF whose diseases advance with every passing day. But never before has the path to the finish line been so clear and well defined. And if there’s one thing we’re good at, it’s racing to the finish line.

The progress is only possible because of the steadfast support of our extraordinary Entourage. Thank you for your belief, your devotion, and your most generous support. You’ve allowed us to transform hope and urgency into tangible outcomes.

Let’s mark this era with fast, transformative breakthroughs!

With profound gratitude,
Liza and Emily

P.S. As you read this report, please note that most information is specific to 2022 and 2023. For clarity, we have included some 2024 information where there have been major shifts or updates in recent months.